Previous 10 | Next 10 |
WARREN, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, is presenting data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-c...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Results Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the ȁ...
Results to be Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or ...
The FDA has granted Orphan Drug Designation to Bellerophon Therapeutics' (NASDAQ: BLPH ) nitric oxide for the treatment of Idiopathic Pulmonary Fibrosis (IPF). More news on: Bellerophon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
WARREN, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designat...
WARREN, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate ove...
Bellerophon Therapeutics (NASDAQ: BLPH ): Q2 GAAP EPS of -$0.06 in-line. More news on: Bellerophon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WARREN, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the three and six months ...
WARREN, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has completed enrollment for Cohort 2 of its ongoing Phase 2/3 random...
News, Short Squeeze, Breakout and More Instantly...
Bellerophon Therapeutics Inc. Company Name:
BLPH Stock Symbol:
NASDAQ Market:
Bellerophon Therapeutics Inc. Website:
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...